McClellan Michael James 4
4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 19, 2019
Insider Transaction Report
Form 4
McClellan Michael James
EVP, Chief Financial Officer
Transactions
- Exercise/Conversion
Ordinary Shares
2019-03-17+660→ 12,990.272 total - Sale
Ordinary Shares
2019-03-18$16.63/sh−230$3,824→ 12,760.272 total - Exercise/Conversion
Restricted Share Units
2019-03-17−660→ 661 total→ Ordinary Shares (660 underlying)
Footnotes (6)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.5800 to $16.6800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]Restricted share units were granted on March 17, 2016, with 660 vesting on each of March 17, 2018 and March 17, 2019 and 661 vesting on Mach 17, 2020.